Audiometric monitoring of cis-platinum ototoxicity

Brown, Randall L.; Nuss, Robert C.; Patterson, Ruth; Irey, Jan

doi:10.1016/0090-8258(83)90100-2

Cited by 26 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The control animals (wild-type Sahlin strain) also had significantly elevated hearing thresholds at all frequencies measured in the high-dose group, but only at the two higher frequencies (14, and 28 kHz) in the low-dose group. This is consistent with earlier studies showing dose-related hearing loss, both in animals and human beings [Brown et al, 1983;Laurell and Jungnelius, 1990;McAlpine and Johnstone, 1990;Rademaker-Lakhai et al, 2006].…”

Section: Discussionsupporting

confidence: 82%

Augmented Ototoxic Effect of Cisplatin in Heterozygotes of the German Waltzing Guinea Pig

et al. 2007

View full text Add to dashboard Cite

It has previously been demonstrated that the carriers of the German waltzing guinea pig are less susceptible to noise trauma. To explore whether this represents a general resistance to inner ear trauma, carriers of the German waltzing guinea pig were exposed to the ototoxic agent cisplatin. Two doses of cisplatin were injected intravenously into anesthetized carriers and weight-matched control animals. Prior to and 96 h after the injections hearing thresholds were established by recording the auditory brainstem responses at 3.5, 7, 14, and 28 kHz. The cochleae were harvested to estimate hair cell loss and to analyze total platinum content. The carriers of the German waltzing guinea pig strain suffered from a more pronounced cisplatin-induced hearing loss compared to the control animals. The results suggest that mechanisms responsible for the protection against acoustic stress do not provide any protection against cisplatin in carriers of the German waltzing guinea pig.

show abstract

Section: Discussionsupporting

confidence: 82%

Augmented Ototoxic Effect of Cisplatin in Heterozygotes of the German Waltzing Guinea Pig

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Other studies have recommended screening only patients with pre-determined risk factors, although these factors vary widely. It is as yet undetermined whether pre-treatment hearing loss does [20,21] or does not [22] contribute to additional loss. Our study found no evidence that underlying hearing loss contributed to additional loss.…”

Section: Discussionmentioning

confidence: 99%

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The overall incidence of high-frequency hearing loss following cisplatin administration ranges from 30 to 50%; progressive involvement of the speech range frequencies has been reported at 15-20%. 6 Generally, these losses are irreversible, 7 although rare reports describe partial recovery over a period of years. 8 An abnormal pre-treatment audiogram, 6 prior cranial radiation 9,10 and increasing cumulative dose of cisplatin [11][12][13] have been consistently predictive of an increased risk of subsequent hearing loss.…”

mentioning

confidence: 99%

“…The role of age, renal function, mode of administration (infusion vs bolus) and concurrent use of other ototoxic agents is less clear. 6,9,[11][12][13] Recently, the myelotoxicity of carboplatin has been overcome by the use of autologous stem cell rescue and/or the use of hematopoietic growth factors, resulting in the use of higher doses of drug to increase anti-tumor efficacy. The impact of higher doses of carboplatin on the incidence of ototoxicity, especially in the pediatric population, is not well characterized.…”

mentioning

confidence: 99%

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

Parsons

Neault

Lehmann

et al. 1998

Bone Marrow Transplant

103

View full text Add to dashboard Cite

Summary:Children with neuroblastoma receiving high-dose carboplatin as part of their conditioning regimen for autologous marrow transplantation have a high incidence of speech frequency hearing loss. We evaluated hearing loss in 11 children with advanced stage neuroblastoma who underwent autologous marrow transplantation, following a conditioning regimen containing high-dose carboplatin (2 g/m 2 , total dose). Audiometric evaluations were obtained at diagnosis, prior to and following transplant. Exposure to other known ototoxins also was assessed. All patients sustained worsening of hearing following high-dose carboplatin. Nine of the 11 children (82%) had evidence of speech frequency hearing loss post transplant for which hearing aids were recommended (grades 3-4). Three of the nine children had speech frequency loss prior to transplant which progressed following transplant. The entire group was heavily pre-treated with platinum-containing chemotherapy pre-BMT and had extensive exposure to other ototoxins, including aminoglycoside antibiotics, diuretics, and noise exposure -all of which could have exacerbated the effects of carboplatin. High-dose carboplatin is ototoxic, particularly in patients who have been primed with previous platinum therapy or other ototoxic agents. We conclude that further efforts are needed to monitor and minimize this complication. In cases where hearing loss is inevitable due to cumulative ototoxic exposures, families need to be adequately prepared for the tradeoffs of potentially curable therapy. Keywords: ototoxicity; neuroblastoma; carboplatin The platinum-containing chemotherapeutic agents play a key role in the treatment of selected pediatric solid tumors. Carboplatin (cis-diammine I, I-cyclobutane dicarboxylato platinum II (CBDCA)), an analogue of cisplatin (cis-dichlorodiammine platinum II (CDDP)), was introduced to clini- 1 Early reports indicated that the incidence of ototoxicity following carboplatin administration might also be lower than that after cisplatin use.1-3 These studies revealed that myelosuppression, not nephrotoxicity, was the dose-limiting toxicity for carboplatin. At the maximum tolerable doses for myelosuppression, single-agent phase I and II studies of carboplatin in adults found a 15% incidence of subclinical hearing loss and a 1% incidence of clinical ototoxicity, primarily manifested as tinnitus.2,3 Similarly, severe hearing loss in children was relatively infrequent. 4 In contrast, the reported incidence of ototoxicity with cisplatin, administered at conventional doses, has ranged from 4 to 91% in different studies.5 Moreover, when hearing loss occurs, it is predominantly in the high-frequency range, although speech frequencies are also affected -occasionally independent of dose or dose rate. The overall incidence of high-frequency hearing loss following cisplatin administration ranges from 30 to 50%; progressive involvement of the speech range frequencies has been reported at 15-20%.

show abstract

Audiometric monitoring of cis-platinum ototoxicity

Cited by 26 publications

References 5 publications

Augmented Ototoxic Effect of Cisplatin in Heterozygotes of the German Waltzing Guinea Pig

Augmented Ototoxic Effect of Cisplatin in Heterozygotes of the German Waltzing Guinea Pig

Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma

Contact Info

Product

Resources

About